Measurement of antabiotic concentration i subcutis and blood in patients receiving ECMO treatment

Concentration of Meropenem in Plasma and Subcutis in Patients on ECMO Treatment - CONECT

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2015-000218-23-DK

Enrollment

Unknown

Registered

2015-03-03

Start date

2015-03-26

Completion date

Unknown

Last updated

2016-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections related to ECMO-hospitalisation MedDRA version: 17.1 Level: PT Classification code 10022519 Term: Intensive care System Organ Class: 10042613 - Surgical and medical procedures

Interventions

Trade Name: Meropenem Pharmaceutical Form: Powder and solvent for concentrate for solution for infusion INN or Proposed INN: MEROPENEM CAS Number: 96036-03-2 Other descriptive name: MEROPENEM Concentr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Signed informed consent - Age = 18 - In treatment with meropenem - Ongoing ECMO-treatment, =65 years) yes F.1.3.1 Number of subjects for this age range 1

Exclusion criteria

Exclusion criteria: - Allergy to meropenem - pregnancy

Design outcomes

Primary

Measure	Time frame
Main Objective: The objective og this trial is to asses the penetration og meropenem into subcutis using the pharmacokinetic tool microdialysis. The primary endpoint is the time above the minimal inhibitory concentration (T>MIC). Secondary endpoints are standard pharmacokinetic parameters.;Secondary Objective: Not applicable;Primary end point(s): Time above the minimal inhibitory concentration (T>MIC) during a dosage interval (8 hours) in respectively plasma and subcutis.;Timepoint(s) of evaluation of this end point: At the end of the study	—

Measure

Time frame

Main Objective: The objective og this trial is to asses the penetration og meropenem into subcutis using the pharmacokinetic tool microdialysis. The primary endpoint is the time above the minimal inhibitory concentration (T>MIC). Secondary endpoints are standard pharmacokinetic parameters.;Secondary Objective: Not applicable;Primary end point(s): Time above the minimal inhibitory concentration (T>MIC) during a dosage interval (8 hours) in respectively plasma and subcutis.;Timepoint(s) of evaluation of this end point: At the end of the study

—

Secondary

Measure	Time frame
Secondary end point(s): Secondary endpoints are standard pharmacokinetic parameters (eg. half-life, Cmax, AUC, Tmax and Vd);Timepoint(s) of evaluation of this end point: At the end of the study	—

Countries

Denmark

Contacts

Public ContactPelle Hanberg

Aarhus University Hospital

pellehanberg@hotmail.com004528744852

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026